RxDoctor Payments Data

Debra Ferguson, NP

Adult Health · Aurora, CONPI 1922198506

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 75 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$304
  • Pfizer$258
  • Amgen$226
  • Cvrx, Inc.$173
  • Boehringer Ingelheim$132
  • E.r. Squibb & Sons, L.L.C.$131
  • plus $496 from 13 others

What the payments were for

  • Food & beverage$1,721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,721 in reported general payments places this provider in the 80th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$47,942
Medicare patients
163
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin498$413,033
EliquisApixaban189$173,690
EntrestoSacubitril/Valsartan164$165,564
FarxigaDapagliflozin Propanediol48$40,995
XareltoRivaroxaban36$36,649
Repatha SureclickEvolocumab18$17,622
Potassium Chloride198$3,948
Metoprolol Succinate347$3,180
Spironolactone419$2,507
Eplerenone27$1,622
Torsemide82$1,540
Prasugrel Hcl19$1,479
Furosemide263$1,315
Hydralazine Hcl59$1,054
Atorvastatin Calcium145$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$132$413,033498 claims
PfizerEliquis$258$173,690189 claims
NovartisEntresto$48$165,564164 claims
AstraZenecaFarxiga$16$40,99548 claims
Johnson & JohnsonXarelto$13$36,64936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →